Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Riya Sinha, Matthew Schwede, Ben Viggiano, David Kuo, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 960.

https://doi.org/10.1182/blood-2023-190151

Published: 2023

Journal Articles

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Emma C St. Martin, Matthew Schwede, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Tian Y. Zhang, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2023-190614

Published: 2023

Journal Articles

Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia

Jesse W. Tai, Guan Li, Kailee Tanaka, Jayakrishnan Gopakumar, Crystal Zhou, Miles Hamilton Linde, Alejandro Villar-Prados, Athreya S Rangavajhula, Aaron C Trotman-Grant, Niklas Landberg, Amy C Fan, Gabriel Mannis, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2023-187981

Published: 2023

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Matthew Schwede, Gladys Rodriguez, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Eran Bendavid, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 958.

https://doi.org/10.1182/blood-2023-187725

Published: 2023

Journal Articles

Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis

Shyam Ajay Patel, William K Gerber, Rena Zheng, Shrinkhala Khanna, Lloyd Hutchinson, Jan Cerny, Brandon Dasilva, Tian Y. Zhang, Salwa Khedr, William Selove, Bruce Woda, Gregory A Abel, Patricia Minehart Miron, Anne Higgins, Jonathan M. Gerber

Blood (2023) 142 (Supplement 1): 4068.

https://doi.org/10.1182/blood-2023-182881

Published: 2023

Journal Articles

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Edna Cheung, Claire Schumann, Tian Y. Zhang, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 5927.

https://doi.org/10.1182/blood-2023-185524

Published: 2023

Journal Articles

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Maria Moscvin, Matthew Schwede, Gabriel Mannis, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4231.

https://doi.org/10.1182/blood-2023-186672

Published: 2023

Journal Articles

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Eric Kuo, Veronica Santiago, Kailee Tanaka, Vikram Puram, Crystal Zhou, Jesse W. Tai, Gabriel Mannis, Ravindra Majeti, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2023-187644

Published: 2023

Journal Articles

Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis

Vishesh Khanna, Tali Azenkot, Selina (Qiuying) Liu, Jason Gilbert, Edna Cheung, Kimberly Lau, Daniel A. Pollyea, Elie Traer, Brian A. Jonas, Tian Y. Zhang, Gabriel N. Mannis

Blood (2022) 140 (Supplement 1): 3294–3296.

https://doi.org/10.1182/blood-2022-166803

Published: 2022

Journal Articles

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, Mia Carleton, Kailee L Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y. Zhang, Michael S. Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David M. Kurtz

Blood (2022) 140 (Supplement 1): 1546–1548.

https://doi.org/10.1182/blood-2022-160370

Published: 2022

Journal Articles

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Irena Tan, Matthew Schwede, Paul Phan, Raymond Yin, Tian Y Zhang, Gabriel N. Mannis

Blood (2021) 138 (Supplement 1): 1216.

https://doi.org/10.1182/blood-2021-147886

Published: 2021

Journal Articles

Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML

Gavin Hui, MD, Abdullah Ladha, MD, Edna Cheung, PharmD, Caroline Berube, MD, Steven Coutre, MD, Jason Gotlib, MD MS, Michaela Liedtke, MD, Tian Y Zhang, MD PhD, Lori S. Muffly, MD MS, Gabriel N. Mannis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-142691

Published: 2020

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

Human Acute Myeloid Leukemia Inhibits Normal Erythroid Differentiation through the Paracrine Effects of IL-6

Tian Y Zhang, MD PhD, Ritika Dutta, BS, Feifei Zhao, MD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 911.

https://doi.org/10.1182/blood-2018-99-119297

Published: 2018

Journal Articles

Direct Contact With Bone Marrow Stromal Cells Protects CML Progenitors From Imatinib Through Cytoplasmic Stabilization Of β-Catenin

Anna M. Eiring, PhD, David J. Anderson, MBA, Tian Y. Zhang, MD, PhD, Ira L. Kraft, BS, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Clinton C. Mason, PhD, Thomas O'Hare, Michael W. Deininger, MD, PhD

Blood (2013) 122 (21): 3982.

https://doi.org/10.1182/blood.V122.21.3982.3982

Published: 2013

Journal Articles

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Anna M. Eiring, PhD, Ira L. Kraft, BS, Brent D.G. Page, PhD, Tian Y. Zhang, MD, PhD, Jamshid S. Khorashad, MD, PhD, FRCPath, Nadeem A. Vellore, PhD, Kimberly R. Reynolds, MS, Anthony D. Pomicter, MS, Anna V. Senina, MS, Matthew S. Zabriskie, BS, Shazia Ahmad, Clinton C. Mason, PhD, Richard Moriggl, PhD, Riccardo Baron, PhD, Thomas O'Hare, Patrick T. Gunning, PhD, Michael W. Deininger

Blood (2013) 122 (21): 854.

https://doi.org/10.1182/blood.V122.21.854.854

Published: 2013

NARROW

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Human Acute Myeloid Leukemia Inhibits Normal Erythroid Differentiation through the Paracrine Effects of IL-6

Direct Contact With Bone Marrow Stromal Cells Protects CML Progenitors From Imatinib Through Cytoplasmic Stabilization Of β-Catenin

BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only